Updates On Relapsing-Remitting Multiple Sclerosis

news-38

Genzyme, a Sanofi company, recently announced novel positive 5-year experimental data from the extension study of Lemtrada® (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS).

Read the findings here: http://bit.ly/1LEWNQV

Leave a Comment

Your email address will not be published. Required fields are marked *